4D Molecular Therapeutics reports clinical, financial and governance developments for a late-stage biotechnology company developing disease-targeted gene therapy product candidates. Its recurring updates center on 4D-150 for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, and on clinical programs such as 4FRONT, PRISM and SPECTRA.
Company news also covers quarterly and annual financial results, cash runway commentary, collaboration and license revenue tied to Otsuka, investor conference participation, board and leadership changes, and employment inducement equity grants. The company states that its product candidates remain in clinical or preclinical development and have not been approved for marketing by the FDA or other regulatory authorities.
4D Molecular Therapeutics (Nasdaq: FDMT) will present and hold one-on-one meetings at seven investor conferences in November and December 2026.
Appearances run from the Guggenheim Healthcare Innovation Conference on November 10 through Barclays Virtual Ophthalmology Day on December 10. Archived webcasts will be available for up to one year in the Investors section of the company website.
4D Molecular Therapeutics (FDMT) granted equity inducement awards to 13 new non-executive employees on October 13, 2026.
The awards comprise options to purchase 260,000 common shares and 157,600 restricted stock units (RSUs). Each option has a $12.36 exercise price, equal to the closing trading price on the grant date. The compensation committee approved the grants under the amended 2025 Employment Inducement Award Plan and Nasdaq Rule 5635(c)(4) to induce new employees to join the company.
4D Molecular Therapeutics (FDMT) will host an Investor Day in New York City on October 21, 2026, starting at 10:30am ET.
The event will cover the clinical profile and commercial vision for 4D-150, with a company presentation, retinal expert panel discussions and a live question-and-answer session. A webcast archive will be available on the company’s investor website for up to one year.
4D Molecular Therapeutics (FDMT) enrolled the first patients in its 514-person 4SIGHT Phase 3 trial of 4D-150 for diabetic macular edema.
The global trial compares 4D-150 with aflibercept 2 mg every eight weeks in previously untreated patients. Its primary endpoint tests whether mean vision change is non-inferior at Week 52. In the earlier SPECTRA trial, nine patients at the Phase 3 dose gained a mean 10.8 vision-chart letters and had a mean 176 µm reduction in central retinal thickness at two years. Among 22 patients assessed for safety, there was no intraocular inflammation or ocular serious adverse events. After three initial aflibercept doses, the nine-patient group received a mean 5.2 supplemental injections versus 13.0 projected with scheduled aflibercept, a reported 61% reduction. The company says a single DME Phase 3 trial could support regulatory filings alongside data from its other trials.
4D Molecular Therapeutics (FDMT) granted equity awards to new employees on September 8, 2026. The compensation committee approved a total of 96,000 Restricted Stock Units (RSUs) for seven new non-executive employees as employment inducement awards.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan, as amended, and are intended to qualify under Rule 5635(c)(4) of The Nasdaq Global Market, which permits equity grants used to induce individuals to enter into employment with the company.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that management will participate in several investor conferences in September 2026. The company will join the Wells Fargo 2026 Healthcare Conference on September 9, the Cantor Global Healthcare Conference on September 10 with a fireside chat at 10:20 a.m. ET, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 with a fireside chat at 5:35 p.m. ET. Archived webcasts of these events will be available for up to one year in the Investors section of the 4DMT website.
4D Molecular Therapeutics (Nasdaq: FDMT) reported that on August 11, 2026, its board compensation committee granted an aggregate 35,200 Restricted Stock Units (RSUs) to five new non-executive employees. The awards were made under the company’s 2025 Employment Inducement Award Plan, in accordance with Nasdaq Rule 5635(c)(4) for equity grants used to attract new hires.
4D Molecular Therapeutics (Nasdaq: FDMT) reported Q2 2026 results and clinical progress, including completion of enrollment for its two global Phase 3 4FRONT trials of 4D-150 in wet AMD, with topline data expected in Q2 and H2 2027. The company presented positive 2‑year PRISM Phase 2b data showing sustained visual and anatomic outcomes with large reductions in treatment burden and an ongoing favorable safety profile. 4DMT plans to initiate a global Phase 3 trial of 4D-150 in DME in Q3 2026 and expects SPECTRA 2‑year DME data in Q4 2026. The company ended June 30, 2026 with $430.6 million in cash, cash equivalents and marketable securities, secured a credit facility with Hercules Capital of up to $200 million (with $20 million initially drawn), and projects funding into at least the second half of 2028. Q2 2026 collaboration revenue was $3.8 million, R&D expenses $68.3 million, and net loss $72.9 million.
4D Molecular Therapeutics (Nasdaq: FDMT) reported positive 2-year results from the PRISM Phase 2b trial of intravitreal gene therapy 4D-150 in a broad wet AMD population. The study enrolled 45 patients at two single-dose levels (3E10 and 1E10 vg/eye), with 3E10 vg/eye selected as the dose for 4FRONT Phase 3 trials.
According to 4DMT, best corrected visual acuity and central subfield thickness were consistently maintained through 2 years, with durable reduction in anti-VEGF treatment burden. The overall cohort showed a 78% reduction in supplemental injections (2.7 vs 12.0 projected with aflibercept Q8W), and the recently diagnosed subgroup showed an 87% reduction (1.6 vs 12.0). In combined Phase 1/2a and 2b safety data at the Phase 3 dose (n=71), 2.8% experienced mild, transient intraocular inflammation within 28 weeks, with no new inflammation cases and no specified serious ocular safety events reported with up to more than 4 years of follow-up.
4D Molecular Therapeutics (Nasdaq: FDMT) reported that on July 14, 2026, the board’s compensation committee granted 37,900 Restricted Stock Units (RSUs) to six new non-executive employees. The awards were made under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).